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1. Introduction 
“Sexual and reproductive health and wellbeing are essential if people are to have 
responsible, safe and satisfying sexual lives. Sexual health requires a positive approach to 
human sexuality and an understanding of the complex factors that shape human sexual 
behaviour. These factors affect whether the expression of sexuality leads to sexual health 
and well- being or to sexual behaviour that put people at risk or make them vulnerable to 
sexual and reproductive ill- health. Health program managers, policy – makers and care 
providers need to understand and promote the potentially positive role sexuality can play in 
peoples’ lives and to build health services that can promote sexually health societies.” – 
(WHO 2006) 
There is increasing number of cancer survivors worldwide. A lot of them experience sexual 
dysfunction for a long time which can last beyond ten years post treatment. Sexual 
dysfunction can occur as a result of any aspect of cancer and cancer treatment. Sexual 
functioning and/or satisfaction have been found to be of concern to many cancer survivors. 
Sexual function can be affected by physical or emotional trauma especially if the genitals are 
affected and can adversely affect the quality of life of the patients. Sexual dysfunction 
includes erectile dysfunction in males and disruption in the sexual response cycle (sexual 
desire, excitement, arousal, orgasm and resolution) and dyspareunia in women. There are 
differences in the pattern of sexual dysfunction between males and females as females may 
be able to cope better than males emotionally. Bonini-Colmano et al. (2007) noted that 
malignant diseases have a strong influence in quality of life, sexuality being one of the most 
affected variables. In their study to determine the prevalence of sexual dysfunction in a 
cohort of patients with cancer and its relationship with the following: pain, fatigue, nausea, 
vomiting, mechanisms of adaptation to stress, anxiety and depression, questionnaires were 
used which included treatment, adverse events, Zimong and Snaith depression and anxiety 
scale, sexual dysfunction questionnaire, coping strategies of Tobin David, Hopwood body 
image scale and the analogical visual test for pain evaluation. Sixty four patients were 
evaluated. Seventy two percent were women and median age was 50 years. Libido was 
absent in 50%; this was associated with gender (better in men; p=0,05) and the presence of 
pain (p=0,05) and fatigue (p=0,05) but not with age. All patients who had intact libido also 
had arousal and orgasms; this was more prevalent in men than in women and in subjects 
younger than 60 years. Arousal was absent in 47% of cases. Forty four percent of men had 
erectile dysfunction; this was present in all patients older than 60 years. Frequency of 
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intercourses was decreased in 75%. Fifty eight percent of patients said that their sexuality 
was better before the diagnosis of their disease. Interestingly, 85% didn't talk to their doctors 
about their sexual problems. The study concluded that one out of 2 patients had sexual 
dysfunction, predominantly women and that sexuality was affected mainly by pain and 
fatigue. Although normal libido was present in all ages, subjects older than 60 years had less 
arousal and orgasms.  
The age of the patients also determines the extent of the problem. Testicular cancer for 
example is more common among youths. At this age group, the patients are either about to 
get married or in early stage of their family life. Sexual problem at this stage can be grievous 
and very traumatizing. Prostate cancer on the other hand is common among the elderly who 
would have completed their family and may be more concerned about survival than sexual 
activities. Sexual issues may therefore not be of prominence among this age group. The site 
of the disease also determines the extent of the problem. A male patient with cancer of the 
penis treated with amputation of the penis will experience more sexual dysfunction than a 
patient with testicular cancer who has a testicle removed. In females, a breast cancer patient 
who had the affected breast removed (mastectomy) will experience more sexuality issues 
than a female counterpart who had only the lump removed (lumpectomy). (Ofman 1995) 
Likewise, a female patient treated for cervical cancer with radiotherapy will experience 
more sexual problems than a female patient treated for head and neck cancer with 
radiotherapy. 
Survivors of cancer of various anatomical sites experience various degrees of sexual 
dysfunction. After treatment, approximately 20% to 30% of breast cancer survivors, 80% of 
prostate cancer survivors, 37% of Hodgkin's survivors, and 58% of head and neck cancer 
survivors report sexual difficulties. (Elyse et al., 2009) Changes in body image, pain, and loss 
of desire result from both cancer and its treatment; long-term physical and psychological 
side effects from cancer treatments can affect sexual functioning. Long-term psychological 
responses, such as depression and anxiety about cancer, may alter the survivor’s ability for 
intimacy and sexuality. 
Sexual dysfunction therefore is an important issue that affects many cancer survivors who 
are increasingly being cared for by health personnel. It is noted that sexual dysfunction 
among these group of patients is never addressed by most of their care givers during follow 
up management. Many effective behavioural and pharmacological treatments for sexual 
dysfunction exist. However, to identify cancer survivors who may benefit from these 
treatments, conversations about sexual dysfunctions must be initiated. Survivors express a 
desire to be able to discuss sexual issues with medical professionals. However, there are 
barriers to these conversations for both patients and physicians. A public opinion poll of 500 
adults in the United States showed that 85% would be willing to talk to their physicians if 
they had a sexual problem. However, 71% did not think that their physicians would be 
responsive or helpful, and 68% were concerned that their physicians would be 
uncomfortable and also reports from some studies found that lack of knowledge, expertise, 
time, and comfort are barriers to these conversations. (Bober et al., 2009) 
2. Aim 
The aim of this chapter is to highlight sexual health  issues among cancer survivors so that 
clinicians and care givers can be able to predict this sequel and incorporate measures as 
early as possible towards prevention, reduction, assessment using appropriate instruments 
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and management of this important condition among patients thereby improving the 
sexuality aspect of their quality of life. 
3. Methods 
Available literature (hard and electronic copies) including the authors work relevant to this 
topic were consulted and evaluated. The sexuality component of the authors work on 
quality of life of head and neck cancer patients seen at The Radiotherapy Department, 
University College Hospital, Ibadan Nigeria (yet to be published ) is  reported . 
4. Findings and discussion  
The findings together with relevant discussion pertaining to common group of malignancies 
are as follows: 
4.1 Female breast cancer survivors 
Breast cancer is a common cancer among women and survival has increased over time 
especially if treatment is commenced early. Five year survival has reached about 97% 
especially in the developed countries with early disease. (Thors et al., 2001) This implies that 
a lot of women will live long and are likely to experience sexual dysfunction. With breast 
cancer the term “survivors” is used here to refer to women who have completed surgery, 
chemotherapy/hormonal  and/or radiation therapy for the treatment of breast cancer. Most 
breast cancer survivors experience about 15% reduction in sexual satisfaction after treatment 
(Bukovic et al., 2005). Approximately 20–30% of breast cancer survivors experience sexual 
problems including general sexual disruption, decreased frequency of intercourse, and 
difficulties reaching orgasm that may persist 20 years post-treatment (Alfano et al., 
2007).The reported  prevalence of this problem varies greatly, partly due to the various 
methods and instruments used in their assessment. In terms of specific sexual difficulties, 
the most common current symptoms reported in this study were absence of sexual desire 
(48%), reduced sexual desire (64%), anorgasmia (44%), lubrication difficulties (42%), and 
dyspareunia (38%) while two or more problems were present in about 97% of the 
participants. These findings show that certain problems appear to be related to the desire 
stage of sexual activity (e.g. loss of interest in sex), while others appear to be related to the 
arousal stage (e.g. lubrication difficulties) and the orgasmic stage (e.g. anorgasmy). 
 In a study among sexually active and recurrence free breast cancer patients who had 
completed surgery, chemotherapy, and radiation therapy, 64%  of the women reported an 
absence of sexual desire, 38% suffered from dyspareunia, and 42% experienced lubrication 
problems Vaginismus, brief intercourse and female orgasmic disorder were reported by 30% 
of the subjects. Thirty-six percent suffered from sexual dysfunction before treatment, which 
worsened in about 27%, while in 49% of women sexual problems arose mainly after 
chemotherapy (26%) or surgery (12%). About one-half experienced changes in the 
relationship with their partner (Barni and Mondin 1997). In another study of breast cancer 
survivors, sexual dysfunction occurred more frequently in women who had received 
chemotherapy and in younger women who were no longer menstruating and depression 
was an important determinant of lower sexual desire, and survivors on antidepressants had 
greater problems with arousal and achieving orgasm. (Melisko et al., 2010)  In a 
retrospective study of breast cancer among young females in Nigeria aged 40 years and 
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below earlier reported by the author, 46 % of the patients reported loss of libido (Ntekim et 
al., 2009). Another study revealed that women diagnosed at age ≤ 40 years had significant 
less sexual interest after treatment than women over 40 years (Morrow, 2011).  
Survivors with upper extremity lymphedema following breast cancer treatment also 
experience sexual dysfunction with upper extremity lymphedema as an additional 
predisposing factor. Sixty-nine women presenting for rehabilitation treatment for upper 
extremity lymphedema (UEL) were assessed by physical examination and validated self-
report assessment instruments measuring demographics, psychological distress, sexual 
functioning, social support, coping style, pain and functional status by Passik and 
colleagues (2007). Their analyses revealed that women with UEL had high levels of 
psychological distress, and high levels of sexual, functional and social dysfunction. There 
were no linear relationships between severity of UEL and levels of distress. Women with 
UEL in their dominant hand, however, had more distress and less overall sexual satisfaction 
than those with UEL in their non-dominant limb. Women with pain of any intensity were 
the most distressed, and had the most significant difficulties in psychological and physical 
functioning. Women with pain also perceived significantly less interpersonal support than 
those without pain. Virtually none were receiving pain treatment. An avoidant coping style 
and low perceived social support were significant correlates of psychological distress. The 
study concluded that UEL poses significant functional, social and sexual functioning 
problems in women following breast cancer treatment and that these patients may also 
benefit from psychological support and sexual therapy in addition to physical rehabilitation.  
There are therefore multiple predisposing factors for sexual dysfunction including pre-
existing sexual problems, negative sexual self-schemas, (cognitive generalizations regarding 
sexual aspects of the self; they represent a core component of one's sexuality) and normal 
age-related changes in sexual functioning. Physical consequences of treatment like absence 
of one breast, scar on the breast and upper extremity lymphedema are also important 
predisposing factors. Partners sexual problems and psychological reaction to the diagnosis 
of cancer are also contributory. Physiologic changes induced by chemotherapy are also 
important contributors. Induction of premature menopause can result in an estrogen 
deficiency state that increases the likelihood of hot flashes and poor vaginal lubrication that 
may contribute to sexual dysfunction (Kaplan, 1991) 
4.1.1 Sexual dysfunction and chemotherapy 
Compared to breast cancer women who were not treated with adjuvant chemotherapy, 
women treated with adjuvant chemotherapy are 5.7 times more likely to report vaginal 
dryness, 3 times more likely to report decreased libido, 5.5 times more likely to report 
dyspareunia, and 7.1 times more likely to report difficulty reaching orgasm.(Ganze etal., 
1998). Chemotherapy therefore affects sexual functioning in women though the extent may 
vary according to different drug regimen and patients age. 
4.1.2 Sexual dysfunction and hormonal therapy 
It has been found that the incidence of vaginal dryness, dyspareunia, and loss of sexual 
interest in women taking Aromatase Inhibitors (AIs) was significant. These symptoms were 
particularly bothersome in women who experienced acute chemotherapy induced 
menopause as reported by Fallowfield et al., 2004. In the 5 year follow up in this study, 
vaginal discharge was less frequently bothersome with anastrozole than Tamoxifen (1.2% 
www.intechopen.com
 
Sexual Dysfunction Among Cancer Survivors 
 
43 
vs. 5.2%) but vaginal dryness (18.5% vs. 9.1%), dyspareunia (17.3% vs. 8.1%), and reduced 
libido (34.0% vs. 26.1%) were all more common with anastrozole compared with Tamoxifen 
(Cella 2006). In the quality of life sub-study for the Intergroup Exemestane Study (IES), loss 
of libido was common and did not differ between groups receiving Tamoxifen for 5 years 
compared to those patients who switched over to exemestane after 2–3 years of Tamoxifen. 
There were no differences between the Tamoxifen or exemestane groups for vaginal 
dryness, discomfort with intercourse, and vaginal irritation (Fallowfield 2006).Even in 
patients without a diagnosis of breast cancer, hormonal therapies appear to have an impact 
on sexual function. Analysis of quality of life data from the Study of Raloxifene and 
Tamoxifen (STAR) prevention trial found that a higher percentage of women randomized to 
the Tamoxifen arm remained sexually active compared to women in the Raloxifene arm. 
Among sexually active participants, women randomized to the Raloxifene group 
experienced significantly more dyspareunia, greater difficulties with sexual interest, sexual 
arousal, and sexual enjoyment, but no significant difference in the ability to experience an 
orgasm  (Land 2006). 
Ganz et al (1999) , found that among women 1 to 5 years post treatment, sexual problems (as 
measured by the CARES and the Watts Sexual Functioning Scale) were more common in 
women who had received chemotherapy. Lindley et al. (1998 as cited in Thors 2001), reported 
an interaction between age and chemotherapy in that the greatest negative change in sexual 
functioning (as measured by a series of questions that included items measuring sexual 
satisfaction and interest) occurred in premenopausal women who experienced chemotherapy-
induced amenorrhea. Under oestrogen deprivation, with time, the mucosal and stromal tissues 
of the vagina, urethra, and trigone of the bladder undergo atrophy, resulting in decreased 
tissue elasticity and fluid secretion. This may lead to symptomatic vaginal dryness and 
irritation as well as dyspareunia. Oestrogen deprivation also leads to an elevation in vaginal 
pH which may increase the risk of vaginal and urinary tract infections.  
4.1.3 Interventions 
Study Instruments: 
A number of study instruments have been used in sexual dysfunction studies in breast 
cancer survivors. The two more commonly used ones are Sexual History Form and the 
sexual summary subscale of the Cancer Rehabilitation Evaluation System (CARES). The 
Sexual History Form was developed by Schover and Jensen (1988, cited in Thors et al., 2001) 
and is composed of 27 multiple choice questions assessing sexual functioning, frequency, 
and satisfaction with sexual activity. This questionnaire has been standardized and norms 
from a healthy community sample are available for comparison purposes. The CARES is a 
quality-of-life instrument that includes an 8-item subscale measuring sexual interest and 
sexual dysfunction. The CARES has been shown to have adequate reliability and validity, 
and normative scores are available for cancer patients (Thors et al., 2001).  
Other study questionnaires include Watts Sexual Functioning Questionnaire (442-13, sexual 
dysfunction subscale of The European Organization for Research and Treatment of Cancer 
[EORTC] QLQ-C30), Derogatis Sexual Functioning Inventory (DSFI), Arizona Sexual 
Experience Scale (ASEX) and Female Sexual Functioning Index (FSFI). Revised Dyadic 
Adjustment Scale can be used to assess partner relationship variables so also with Marital 
Satisfaction Inventory-Revised (MAI-R) (Stead 2003).  
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Communication with women concerning sexual life is vital. Psychotherapy and behavioural 
approaches has been shown to be useful in managing these patients. Pharmacologic agents 
especially non estrogenic topical agents for specific problems like vaginal dryness are 
recommended. However a thorough assessment to determine which aspect of sexual function 
is affected can help in prescribing suitable approach to management. This can be done using 
more detailed study instruments. The commencement of pelvic floor muscle exercises, use of 
vaginal moisturizer to alleviate vaginal dryness and olive oil as lubricant during intercourse 
has been shown to improve sexual function in breast cancer survivors. (Juraskova 2011)  
4.2 Genito-urinary cancer survivors 
Survivors of cancer of the genito-urinary system do experience sexual dysfunction of which 
some are peculiar to affected organs. Some organs like the urinary bladder are closely 
related to sex organs and can directly affect sexual functions during the course of the disease 
and treatment. Post treatment effects like ovarian failure after chemotherapy and pelvic 
radiotherapy in females can have effects on sexual functions of survivors. 
4.2.1 Testicular cancer 
Testicular cancer is the most common cancer of young men in their 20s and 30s. Since the 
advent of effective multiagent  cisplatinum-based chemotherapy, the majority of patients are 
cured. This disease occurs during the peak period of reproductive life and at a key time for 
career and family. As cured testicular patients have a long life expectancy, sexual function 
becomes an important issue. It has been found that hormonal dysfunction is frequent after the 
diagnosis of testicular cancer and treatment can have an additional detrimental effect. This can 
have a significant impact on the sexual life of the survivor and contribute to other health 
problems. Most patients, however, remain fertile though this can be affected by their 
treatment. Long-lasting sexual problems after therapy for testicular cancer are present in 
approximately one-fifth of patients undergoing treatment for testicular germ cell tumour. On 
the other hand, the majority of patients have not reported infertility or sexual dysfunction-
related symptoms (Hartmann et al., 1999). In a study by Huddart and colleagues, the testicular 
module of the EORTC QLQ C-30 Questionnaire, which consists of six questions directed at 
sexual function and sexual satisfaction and two additional questions about masculinity and 
concerns about fathering children, was used. Overall sexual function from the analysis seemed 
to be satisfactory with 83% of patients expressing satisfaction in their sexual relationships with 
their partner with no differences between treatment groups. Compared to surveillance there 
was a tendency for treated groups to have less sexual activity and less interest in sex. This was 
only statistically significant for patients treated with chemotherapy and radiotherapy (CRT) 
and less interest in sex was of borderline significance for CRT and radiotherapy (RT). 
Additionally, radiotherapy treatment was associated with reduced sexual enjoyment 
compared with patients on surveillance (Huddart et al., 2005) The  Derogatis Interview for 
Sexual Functioning-II Self-Report-Male questionnaire can also be used to assess sexual 
dysfunction in males (Greenfield et al.,2010). 
4.2.2 Prostate cancer 
Erectile dysfunction is common after prostatectomy because of the interference with the 
nerves. The extent being different with different methods of surgery as some have more 
nerve sparing effects than others. 
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In comparison with prostatectomy, patients treated with external beam radiation report less 
long-lasting urinary symptoms, but more bowel side effects, with no difference in global 
quality of life. Sexual disorders are initially less important with external beam radiation but 
increase over time. Brachytherapy shows no sexual function preservation benefit relative to 
external beam radiation and may be less favourable with more urinary sequelae. The 
association of hormonal therapy and external beam radiation decreases the quality of life of 
the patients, with a negative impact on vitality, sexuality and increase urinary disorders. 
Intensity-modulated radiotherapy (IMRT) seems to better preserve the long-term digestive 
quality of life in comparison with conformal radiation therapy (Joly et al., 2010).  
Radical surgical prostatectomy for cancer is performed by the perineal, retropubic, or 
transpubic routes. Surveys of patients undergoing either retropubic or perineal 
prostatectomy have reported comparable findings, with estimates of diminished erectile 
capabilities or complete erectile failure after surgery for 90% of the patients. The incidence of 
ejaculation difficulties with or without concomitant erectile failure is estimated as occurring 
for 78% of the retropubic and 100% of the perineal prostatectomy patients. If hormone 
therapy and/or orchiectomy are additionally used after either surgical procedure, virtually 
100% of the patients experience erectile failure and ejaculation difficulties. These estimates 
are three to four times higher than those for patients treated for benign conditions with less 
extensive surgery (Andersen 1985). The sexual domain of the Expanded Prostate Cancer 
Index (EPIC) questionnaire can be used to assess prostate cancer survivors.  
4.2.3 Bladder cancer 
Early bladder cancer is treated by transurethral resection and there may be minimal sexual 
dysfunction. Cystectomy is associated with reduction in desire and erectile function in about 
30% of male patients while sexual excitement and orgasm is impaired in women. (Anderson 
1985)  A comprehensive, disease specific measure of health related quality of life in patients 
with localised bladder cancer has been developed by Gilbert et al., (2010). 
4.3 Gynaecological cancer survivors 
Modalities of treatment comprising of surgery, chemotherapy, radiotherapy and hormonal 
therapy either single or in various combinations are used to treat gynaecological malignancies. 
All these modes have the potential to affect sexual functions of the patients. Gynaecological 
malignancies have the ability to affects a woman’s sexual wellbeing primarily as the sexual 
reproductive organs are involved. Altered sexual functioning is the most affected aspect of 
quality of life of gynaecological cancer survivors occurring in 40-100% of patients compared to 
19%-50% of the healthy outpatient population (Andersen, 1985). 
4.3.1 Cervical cancer 
The two modes of treatment for early disease, radical hysterectomy and radiation therapy, 
are equally common for early stage cervical cancer. Surgical treatment allows ovarian 
preservation for premenopausal women, but does cause vaginal shortening, which has 
contributed to coital discomfort (Andersen & Hacker 1983). Radiation therapy destroys 
ovarian functioning and causes vaginal atrophy and stenosis. Dyspareunia from lack of 
lubrication, tenderness of the vagina, and post coital bleeding have been resultant problems. 
Comparable outcome with 29% and 33% of radiation and hysterectomy patients, 
respectively, reporting subsequent sexual difficulties have been reported (Andersen 1985). 
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Some studies demonstrated that women with early stage cervical cancer receiving 
hysterectomy and radiotherapy suffered a number of short-term sexual difficulties such as 
dyspareunia, problems during intercourse and lack of sexual satisfaction, but that by 6 
months after the surgery these problems had often reduced. However, some sexual 
difficulties persisted, in particular lack of sexual interest and lack of lubrication. In contrast, 
women with advanced, recurrent, or persistent cervical cancer experienced prolonged 
problems with vaginal lubrication, lack of orgasm, and lower frequency of intercourse, in 
addition to reduced sexual interest, throughout the 24 months post diagnosis (Stead 2004) 
The Female Sexual Function Index (FSFI) questionnaire and ALARM model are useful 
questionnaires to assess sexual function in these patients (Andersen 1990).  
In a study by Lindau ST et al.( 2007 )sexual problems were significantly more prevalent among 
very long term  (>25 years) survivors of cervical and vaginal cancers than in  population-based 
comparison group. For example, the prevalence of dyspareunia (pain during intercourse) and 
difficulty lubricating were, respectively, nearly 7 and 3 times higher among survivors. 
Survivors were also significantly more likely than those in the population-based sample to 
exhibit complex sexual morbidity, defined as concurrent sexual problems in three or more of 
seven domains , and to report avoiding sex because of sexual problems (62% versus 43%). In 
the same study, 62% of survivors reported that a doctor had never initiated a conversation 
about the effects of cancer or treatments for genital tract cancer on sexuality and Bivariate 
analysis revealed that a conversation with a physician about the sexual effects of genital tract 
cancer and cancer treatment is associated with significantly fewer sex morbidities. Some 
studies show that education on vaginal lubricants, moisturizers, and dilator use (as needed) 
can decrease the morbidity of vaginal atrophy (Carter et al., 2011). 
4.3.2 Vulval cancer 
Surgical treatment is commonly used for treating vulval carcinoma. This has some effects on 
sexual performance of the patients and various patterns of sexual dysfunction have been 
reported. A survey of 18 patients treated with wide local excision rather than vulvectomy 
for microinvasive disease indicated that all women continued to be orgasmic during sexual 
activity, in contrast to two radical vulvectomy patients who reported loss of orgasmic ability 
and dyspareunia. (Andersen 1985) A retrospective study of women who received radical 
surgery indicated discrepancies between the actual and the preferred frequency of sexual 
activities such as intercourse and a limited capacity for sexual arousal among these patients. 
Interestingly, orgasmic responsiveness is reported by women who had and who had not 
undergone clitoral excision at the time of vulvectomy (Thuesen et al., 1992). Another study 
has shown that more than half of women with vulval cancer experience sexual problems, 
with those women undergoing local vulval excision for vulval dysplasia experiencing the 
most problems. While these, in part, are related to anatomic changes, inadequate 
counselling and poor advice were contributing factors. A small study described how 
vulvectomy was associated with altered body image and arousal difficulties, and suggested 
that risk factors for sexual problems were age, depression, poor performance status, and 
preoperative sexual dysfunction. These findings demonstrate the need for appropriate 
counselling and advice for women with vulval cancer. (Green et al., 2000) 
4.3.3 Endometrial cancer 
Women with endometrial cancer are usually older and postmenopausal and their treatment 
often involves surgery plus radiotherapy and so surgery and radiation induced vaginal 
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difficulties can occur. The pattern of sexual difficulties may be similar to those with cervical 
cancer of similar age group. 
4.3.4 Ovarian cancer 
Ovarian cancer is usually treated with a hysterectomy (including oophorectomy), and 
chemotherapy. Few of them also have adjuvant radiotherapy. These can all affect sexual 
functioning, through a decrease in oestrogen production resulting in vaginal atrophy and 
dryness. There can be hot flushes and loss of sexual interest resulting from changes in body 
and hormonal levels especially if the patients were pre menopausal prior to treatment. A 
study of 200 survivors of ovarian cancer showed that over 50% reported worsened sexual 
function (Stewart et al., 2001) 
A cross-sectional study  in 232 women with ovarian cancer showed that ovarian cancer is also 
associated with low sexual desire (47% reported no/little desire), vaginal dryness (experienced 
in 80% of women having sexual intercourse in the last month), dyspareunia (in 62%), and 
problems with orgasm (in 75%). This study also evaluated predictors of sexual activity and 
found that being married, being under 56 years, not receiving treatment, good self-
esteem/body image, and length of time since end of treatment were all associated with being 
sexually active. This paper compared the findings of the research with studies in breast cancer 
and healthy postmenopausal women and concluded that although low desire, vaginal 
dryness, and dyspareunia occur in these other groups; the problems are more common and 
more severe in women with ovarian cancer. (Stead, 2004). A study of survivors of ovarian 
cancer found that about 80% of them who were sexually active before treatment reported 
vaginal dryness. This can lead to dyspareunia and subsequent fear of possible pain during 
vaginal penetration may contribute to the loss of interest in sex. (Carmack-Taylor et al., 2004). 
EORTIC QLQ OV 28 is a useful questionnaire in assessing sexual dysfunction among 
ovarian cancer survivors. 




b Vaginal dryness and size changes  should not occur if one ovary is retained or if hormone therapy is 
given. 
Table 1. Female sexual problems caused by cancer treatment. (Adapted from American 
Cancer Society Inc. 2009 as cited in Audette and Waterman 2010). 
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4.4 Gastro intestinal cancer survivors 
Survivors of gastrointestinal malignancies also experience sexual disorders. Although 
studies in most sites are not easily available, few reports show that survivors of these cancer 
site also experience sexual dysfunction. 
4.4.1 Colorectal cancer survivors 
Colorectal cancer is quite common all over the world including Europe and America. 
Surgical resection is an effective treatment modality for early diseases. The surgical 
approach differs according to the location of the tumour. Low lying tumours are located 0-5 
cm from the anal verge and abdomino- perineal resection is the approach commonly used 
resulting in permanent colostomy. A review by Sprangers et al. (2003) noted that this 
operation disrupts nerve fibres associated with sexual function more in men than in women. 
It also noted that low or high anterior resection used in the treatment of tumours  located 
more than 5cm from the anal verge (lower or upper colon) which are sphincter sparing, also 
disrupts some nerves associated with sexual function especially if ultra low anastomosis are 
used. In a study on survivors after chemo-radiotherapy for rectal cancer using EORTIC 
QLQ-CR38, The scores for "sexual functioning" and "enjoyment" were low. Men had more 
sexual problems than females (62.5 vs. 25 mean scores respectively). (Tiv et al, .2010). 
Erectile dysfunction was also reported among men and the presence of colostomy was 
reported to further reduce sexual functioning in males but not in females.  
Several retrospective studies of sexual functioning after excision of the rectum for cancer 
have been conducted. For men, estimates of sexual dysfunctions have ranged from 32% to 
59% for sexual desire, from 28% to 76% for erectile difficulties and from 66% to 86% for 
ejaculation disruption (Andersen, 1985). Estimates for women from one investigation 
reported that 28% of the sample had reduced desire and 21 % reported genital numbness or 
dyspareunia. (Kuchenhoff 1981 as cited in Andersen 1985) 
Laparoscopic surgical techniques have been used in resection of colorectal cancers with 
reported equivalence in tumour clearance with conventional open techniques. It has 
additional advantage of less pain, reduced hospital stay and earlier return to normal 
function. In a retrospective assessment for rectal dysfunction in colorectal cancer patients 
who had laparoscopic resection, Aquah et al. (2002) reported that a significant difference in 
sexual function in males but not females was noted. Seven of the 15 sexually active men in 
the laparoscopic group reported impotence or impaired ejaculation while only one of the 22 
patients in the open surgery group had such complain. (P=0.004). The study concluded that 
laparoscopic resection of colorectal cancer was associated with more sexual dysfunction 
than open surgical resection. 
4.4.2 Hepatocellular cancer (HCC) 
Patients with hepatocellular carcinoma also experience sexual dysfunction. In a study by 
Steel et al., (2005) comparing sexual dysfunction among hepatocellular cancer patients and 
chronic liver disease (CLD) patients, reported that with regards to the differences between 
HCC patients and those with CLD with respect to sexual problems, the rates of sexual 
morbidity were found to be higher in patients diagnosed with HCC for the majority of the 
sexual problems, including hypoactive sexual desire disorder (26% vs. 18%), sexual aversion 
disorder (18% vs. 5%), male orgasmic disorder (13% vs. 5%), premature ejaculation (17% vs. 
5%), and dyspareunia (12% vs. 5%). The only disorder in which CLD patients reported a 
higher prevalence than HCC patients was male erectile disorder (21% vs. 17%) Male patients 
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had more sexual problems than the general population. The study also noted that co morbid 
conditions like hypertension, diabetes mellitus and cardio vascular diseases were more 
prevalent among HCC patients and medications for these conditions could add to their 
sexual problems. 
4.4.3 Anal cancer  
Majority of patients treated for anal cancer experience sexual dysfunction. A study using 
split course chemo radiotherapy for the treatment of anal cancer among 58 patients reported 
that fifty percent of patients maintained an interest in having sexual relations but 100% of 
male patients had difficulty maintaining an erection. Forty-four percent of men qualified the 
erectile dysfunction as severe (# 4 on the scale: very much). Among women, 65% had no 
interest at all in sexual relations, 21% a little, and only 14% had a moderate interest. For 
those women who maintained an interest in having sexual relations, 50% reported having 
pain or discomfort during intercourse. The majority of the patients did not suffer from non-
satisfaction regarding their body or loss of masculinity or femininity in relation to their 
cancer or the treatment (Provencher et al., 2010). 
4.5 Haematological cancer survivors 
Survivors of haematological cancers including lymphoma do also experience sexual 
dysfunction especially those treated with bone marrow transplant. (Haematopoetic Stem Cell 
Transplant - HSCT). These patients usually receive cytotoxic chemotherapy and or whole body 
irradiation to suppress graft versus host reaction. Jean et al. (2009) in an extensive review of 
this aspect among survivors of HSCT noted that “these treatments impair the production of 
testosterone at least for the first year for males, and induce ovarian failure for most women. 
Effects are not solely gonadal. Treatments are known to permanently damage function of the 
hypothalamic-pituitary-gonadal axis. Luteinizing hormone (LH) is elevated in most female 
survivors and normal in most males. Follicle stimulating hormone is elevated in over 90% of 
females and most males. Most females have primary ovarian failure with consequent low 
endogenous oestrogen levels, and vaginal tissue atrophy is a risk. Chronic GVHD (Graft 
Versus Host Disease) may also contribute to vaginal introital stenosis and mucosal changes 
that contribute to dyspareunia, vaginal irritation, and increased sensitivity of genital tissues. 
Male sexual problems have been attributed to gonadal and cavernosal arterial insufficiency 
with resulting libido and erectile dysfunction.” These reactions are mostly noted with 
alkylating agents class of cytotoxic drugs. 
The lymphomas (Hodgkin's lymphoma [HL] and non-Hodgkin's lymphoma [NHL]) are 
among the most common cancers affecting men under 45 years. Survival rates are now 
excellent, but treatment is associated with a number of side effects including sexual 
dysfunction with potential implications for compromised quality of life (QoL). A study was 
carried out to address (i) the prevalence of sexual dysfunction among lymphoma survivors 
relative to the general population, survivors of other cancers, and in survivors of HL and 
NHL; and (ii) relationships between sexual functioning and disease and treatment, 
demographic, and psychological variables. Sexual function was found to be compromised 
relative to the general population, better than testicular cancer survivors, and worse than 
leukemia survivors. Depression was consistently associated with sexual dysfunction. There 
was evidence that chemotherapy, relapse, reduced testosterone levels, older age at survey, 
and worse physical QoL were associated with worse sexual function (Arden-Close et al., 
2011). Another study found out that sexual problems were commonly reported by HL 
www.intechopen.com
 
Sexual Dysfunctions – Special Issue 
 
50
survivors, with 54.2% reporting decreased sexual activity and 41.4% reporting decreased 
interest. In the long term, this study did not show any difference in sexual function in long 
term survivors compared with the general population (Reclitis et al., 2010). However in 
another study on male lymphoma using Brief Sexual Function Index (BSFI) questionnaire, 
survivors had a mean age at survey of 47.4 years, the mean duration of follow-up was 14.8 
years, and 79% lived in committed relationships. All BSFI domain scores decreased 
significantly with age. Lymphoma survivors also had low testosterone and/or elevated LH 
and had lower BSFI scores than survivors with normal gonadal hormones. Multivariate 
analyses showed that increasing age, more emotional distress, poor physical health, and low 
testosterone and/or elevated LH were significantly associated with reduced sexual function 
within the lymphoma group. Lymphoma survivors had significantly lower BSFI domain 
scores than did controls on erection, ejaculation, and sexual satisfaction (Kiserud et al., 
2009). Erectile dysfunction has also been reported in 61% of lymphoma survivors assessed at 
least two years after treatment. (Aksoy et al., 2008). An earlier report found that 
chemotherapy for Hodgkin's disease produces ovarian failure in young women. The 
consequences of this are emotional distress, sexual dysfunction, and the disruption of 
families and friendships. These side effects of cytotoxic therapy had developed in 25 of 41 
patients, among whom retrospective study was conducted (Chapman et al., 1979). 
Chemotherapy for Hodgkin's disease in that era however consisted of largely alkylating 
agents. Current combinations may not have such marked effects on ovarian function. 
4.6 Central nervous system survivors 
Survivors of brain tumours also experience sexual dysfunction. Neuroendocrine disturbances 
in anterior pituitary hormone secretion are common following radiation damage to the 
hypothalamic-pituitary (H-P) axis, the severity and frequency of which correlate with the total 
radiation dose delivered to the H-P axis and the length of follow-up. The somatotropic axis is 
the most vulnerable to radiation damage and GH deficiency remains the most frequently seen 
endocrinopathy. With low radiation doses (<30 Gy) GH deficiency usually occurs in isolation 
in about 30% of patients, while with radiation doses of 30-50 Gy, the incidence of GH 
deficiency can reach 50-100% and long-term gonadotropin, TSH and ACTH deficiencies occur 
in 20-30, 3-9 and 3-6% of patients, respectively. With higher dose cranial irradiation (>60 Gy) 
or following conventional irradiation for pituitary tumours (30-50 Gy), multiple hormonal 
deficiencies occur in 30-60% after 10 years of follow-up. Precocious puberty can occur after 
radiation doses of <30 Gy in girls only, and in both sexes equally with a radiation dose of 30-50 
Gy. Hyperprolactinaemia, due to hypothalamic damage is mostly seen in young women after 
high dose cranial irradiation and is usually subclinical. H-P dysfunction is progressive and 
irreversible and can have an adverse impact on growth, body image, sexual function and 
quality of life. Regular testing is advised to ensure timely diagnosis and early hormone 
replacement therapy (Dalzy and Shalet, 2009). A prospective trial of the methods of sexual 
rehabilitation of 31 men with pituitary tumours has shown that therapy with testosterone and 
chorionic gonadotropin effectively corrects hypogonadism and sexual disorders. In insufficient 
efficacy, normalization of sexual function is achieved with tadalafil. Both methods of treatment 
had no negative effect on the size of the prostatic gland and PSA level except 2 patients with 
somatotropinoma on testosterone. In the course of chorionic gonadotropin treatment pituitary 
tumour increased in size in 3 patients (Rozhivanov & Kurbatov 2010). There is a case report of 
a 39-year-old patient with a history of high-grade anaplastic astrocytoma who presented to the 
Sexual Health Program at the Memorial Sloan-Kettering Cancer Center complaining of vaginal 
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discharge and several months of amenorrhea. Although the patient was administered 
extensive aggressive antineoplastic treatments, her disease rapidly progressed. She was found 
to have mild vaginal atrophy and had improved sexual function after treatment which 
consisted of intravaginal non-hormonal moisturizers and vaginal lubricants, counselling, and 
sexual education (Krychman et al.,2004). 
4.7 Survivors of sarcoma 
Sarcomas of soft tissues and bones/ cartilages are usually treated with surgery (if possible 
depending on the site), radiotherapy and sometimes with chemotherapy consisting of 
vincristine, cyclophosphamde, doxorubicine with or without actinomycine D. Chemotherapy 
especially  cyclophosphamide has been reported to be associated with low sperm count and 
raised follicle stimulating hormones in males . Exposure before puberty was not found to be 
protective and infertility was associated with high doses of cyclophosphamide. (Kenny et al., 
2001) Total sacrectomy and reconstruction for patients with osteosarcoma, chondrosarcoma, 
giant cell tumour and chordoma in the sacral region is associated with high degree of sexual 
dysfunction likely due to disruption of the nerves around the site. (Wuisman et al., 2000) 
4.8 Head and neck cancer survivors 
Survivors of head and neck cancers also have sexual dysfunction. In a study involving 55 
participants, eighty-five percent showed interest in sex. Fifty-eight percent were satisfied with 
their current sexual partner and 49% were satisfied with their current sexual functioning. 
Majority reported arousal problems, 58% did not participate in sexual intercourse, and 58% 
had orgasmic problems. Most patients were not depressed. There was no correlation between 
sexual functioning and performance status or severity of disfigurement. Patients younger than 
65 years of age had more advanced disease, lower performance status and significantly poorer 
sexual functioning; those older than 65 years were more satisfied with their sexual partner and 
current sexual functioning (Monga et al, 1997). 
Study instruments used in studies among head and neck cancer patients include Derogatis 
Sexual Function Scale, EORTIC QLQ  H&N 37 sexual subscale 
A quality of life studies among head and neck cancer survivors has been carried out at the 
Radiotherapy Department of The University College Hospital Ibadan Nigeria by the author. 
The aim of the study was to compare the quality of life pre treatment with quality of life  at 
least  9 months  post treatment  of head and neck cancer patients seen at the centre. The 
materials and methods used included the assessment and evaluation of head and neck 
cancer patients that presented for treatment. All patients evaluated had histological 
confirmation of their conditions .Those with ECOG performance status greater than 2   or for 
palliative treatment were excluded as well as patients that were HIV positive. To study the 
sexuality component, The EORTIC H&N QLQ 35 questionnaire was used. There are only 2 
questions that relate to the sexuality domain in the instrument and these are questions: 
 
29. Have you felt less interest in sex? And 30. Have you felt less sexual enjoyment? These 
were assessed on a 4 point Likert scale as follows: 
 
Not  at all     A little     Quite a bit      Very much 
1                 2                   3                       4 
The questionnaires were administered before commencement of treatment and at least 9 
months after treatment during follow up visits. 
www.intechopen.com
 
Sexual Dysfunctions – Special Issue 
 
52
A total of 100 patients were evaluated. The characteristics of the patients are presented in 
table 2. 
 
Age group distributions 







































Table 2. Head and Neck Quality of Life (Sex) studies : Patients’ characteristics. (N=100)  
The overall mean age was 49.86 years with a range of 18-85 years and Standard Deviation 
(SD) = 17.48. Mean age for males = 51.59 years, range = 19-85 years and SD = 16.93 while 
mean age for females = 47.60 years with a range of 18-85 years and SD = 18.39. The pre-
treatment and post treatment scores are presented in table 3 
 



























































Table 3. Head and Neck Quality of Life ( Sex) Scores (N=100 ) 
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These results show that there were reduction in sexual functioning in all the patients after 
treatment for head and neck cancers and these were noticed with all cancer sites. Survivors 
of cancers of the Sino-nasal region experienced the highest sexual problems followed by 
those with laryngeal cancers among the core head and neck cancer patients. Survivors of 
thyroid cancer however had the highest score of sexual dysfunction and it is better 
considered separately as endocrine cancers since hypothyroidism can result in sexual 
dysfunction. Patients with advanced diseases (stages 111 &1V) experienced more sexual 
problems than those with early diseases (stages 1 & 11).[P value 0.47]  This is similar to 
earlier reports by Monga et al.,(1997) who reported poorer sexual function among patients 
with advanced disease which was more in those 65 years and above. The result also shows 
that the effect was more on females than males (P value 0.21). This may probable be due to 
the use of chemotherapy which may have more effects on the hormonal status of the female 
patients. Some chemotherapy agents affect the ovaries leading to reduction in the amount of 
circulating oestrogen. This leads to reduced sexual functions. Ovarian failure occurs most 
often in women who are above 35 years of age after chemotherapy (Schover, 2008). 
The reported changes in sexuality is important because the mean age of these patients was 
49 years which means that these patients are relatively young and therefore sexually active, 
as this is an important  social aspect for many of them. 
This analysis gives an indication that these patients have sexual issues following treatment. 
These issues need to be addressed by care givers. More detailed study focussing on 
sexuality of survivors using questionnaires that can evaluate specific aspects of sexual 
function is required for better assessment and management of survivors of head and neck 
cancers in this environment. 
4.9 Lung cancer survivors 
Sexual problems exist among survivors of lung cancer. A report noted that sexual concerns 
were common, with 52% of patients reporting at least mild sexual concerns and were stable. 
Sexual concerns were significantly associated with physical and emotional symptoms. 
Particularly strong relationships were found between sexual concerns and shortness of 
breath and emotional distress. Age moderated the relationship between both fatigue and 
shortness of breath and sexual concerns. Gender moderated the relationship between 
emotional distress and sexual concerns. Self-reported sexual concerns were noted to be 
common in people with lung cancer, are stable, and are related significantly to physical and 
emotional symptoms. Age and gender influenced the distress associated with sexual 
symptoms in this population.(Reese et al., 2011) 
4.10 Management of sexual dysfunction 
It is important that sexual issues be looked into among cancer patients especially after 
treatment. During the course of the disease, lots of issues like anxiety concerning the disease 
and its treatment, financial issues, employment related issues and other social issues may 
affect sexual health of the patients. Those who have completed their treatment will be free 
from many other co- founding problems and sexual issues will come to the fore. These have 
to be addressed as part of the patients’ management. It is also pertinent to note that these 
issues vary in intensity with respect to duration of survival hence periodic reassessment 
needed for necessary adjustments in pattern of care. 
www.intechopen.com
 




Cancer survivors should be assessed for sexual dysfunction before treatment and as soon as 
they are clinically stable. It is important to know the pre treatment sexual functioning of the 
individual as this varies from person to person. This baseline information will also enable 
the health personnel to assess the degree of variation ascribable to the disease and its 
treatment. Anxiety and depression associated with the illness should be identified and 
managed before addressing sexual concerns. There is also need to distinguish cancer 
patients with sexual difficulties and concomitant psychosocial stressors (e.g., financial, 
familial, occupational, marital). These latter difficulties could disrupt the range, frequency, 
enjoyment, or importance of sexual activity for cancer patients as they sometimes do for 
healthy individuals.) from those without additional stressors, allowing more specific 
etiologic associations to be identified 
Discussions on  survivors sexual  health can be commenced using  some tools like:- 
PLISSIT model—Permission, Limited Information, Specific Suggestions and Intensive 
Therapy. This model involves four stages to guide the assessment and treatment of sexual 
dysfunction. The first stage, permission, involves providing the patient with an opportunity to 
discuss sexual problems or concerns. Limited information involves the provision of general 
information about the sexual problem and options for intervention. Specific suggestions would 
include detailed discussions about treatment options and techniques that could be used to 
improve sexual activity. Intensive Therapy usually involves referral to a specialist. This model 
can be used to systematically guide the healthcare professional through the evaluation of 
sexual dysfunction and the provision of information. (Stead 2004) ALARM model- Activity, 
Libido, Arousal, Resolution, Medical information. Communication has to be initiated by the 
health care personnel with the patients concerning the above aspects of their sexual lives in 
order to establish possible areas of intervention. PLEASURE model –Partner, Lovemaking, 
Emotions Attitude, Symptoms, Understanding, Reproduction Energy.  
BETTER model- Bring up the topic, Explain that sexuality is an important aspect of quality 
of life and should be discussed, Tell patients that there are resource s available to address 
concerns or problems,  Timing is important, offer discussions and let them know you are 
available anytime, Educate patients and families how treatment can  impact  sexuality, 
Record discussions , assessment, interventions and outcomes (Audette & Waterman 2010).  
These tools can be applied for general screening of patients for sexual dysfunction and it is 
recommended that this assessment should be done periodically to monitor the patients. 
Detailed diagnostic tools could then be applied in those with established problems for more 
specific diagnosis based on disease site and patients characteristics. A list of some other 
tools that can be used to assess various aspects of sexual dysfunction is provided in table 4.. 
4.10.2 Treatment 
Some physical therapy like exercises can help in the treatment of some forms of sexual 
dysfunction as part of general well being resulting from exercise. Specific exercises like 
pelvic floor exercises can promote relaxation and help in relieving dyspareunia following 
treatment of some gynaecological malignancies. Intercourse should be encouraged at least 
three times per week following pelvic irradiation in women. Alternatively, vaginal dilators 
of fingers can be used at least three times per week for ten minutes to keep the vaginal canal 
patent. This is also useful towards follow up examinations (Borduka & Sun 2006). 
Pharmacological agents like non steroidal lubricants for women are also available for those 
experiencing vaginal dryness. Psychological therapy especially by specialists can improve 
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the situation. Hormonal replacements may be useful especially in some hormone associated 
conditions like following treatment for pituitary tumours and other endocrine malignancies. 
 
Name of Questionnaire Author(s) Original 
language 
Arizona Sexual Experience Scale  Gelenberg, A. English 
Brief Index for Sexual Functioning for 
women (BISF-F) 
Rosen ,R. English 
Brief Sexual Function Index (BSFI) O’Leary, M. English 
Changes in Sexual Functioning 
Questionnaire (CSFQ)- F & M 
Components 
Clayton ,A English 
Derogatis Index for Sexual Functioning 
(DISF) M & F 
Derogatis, L English 
Erectile dysfunction Inventory of 
Treatment Satisfaction (EDITS) 
Altof S Et al., for Pfizer Inc English 
Erectile Dysfunction Quality of Life ED 
EQOL 
Mac Donagh English 
Erectile Dysfunction Question (EDQ) Araujo, A. English 
Female Sexual Desire Profile (FSDP) Nillson ,A. English 
Female Sexual Distress Scale (FSDS) Derogatis, L. English 
Female Sexual Distress Scale  
(FSDS)– Revised 2005 
Derogatis, L. English 
Female Sexual Encounter Profile - 
adapted (FSEPa) 
Ferguson  D. English 
Female Sexual Function Questionnaire 
(FSFQ) 
Quirk, F English 
Female Sexual Function Index (FSFI) Rosen ,R & Ferguson D English 
International Index of Erectile Function 
(IERF) 
Rosen, R for Pfizer Inc English 
International Index of Erectile Function 
(IERF)- Partner Diary 
 Rosen ,R. For Pfizer Inc English 
Inventory of Treatment satisfaction (ITS) Althof et al. English 
Mc coy Sexuality Questionnaire (MFSQ) Mc Coy, N. English 
MOS Sexual Function Module  
(MOS-SEXUAL) 
 Ware Dr. English 
Psychosexual Daily Questionnaire (PDQ) Wang, C. English 
Sexual Activity Questionnaire (SEXACQ) Fallowfield L English 
Sexual Function Index (SFI) O’Leary English 
Sexual Life Quality Questionnaire 
(SLQQ) 
Lass, S. English 
Sexual Satisfaction Module (SEXTES) Testa, M. English 
Table 4. Specific Questionnaires: Sexuality. Adapted from Mapi Institute (n.d.) 
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The prevalence of sexual dysfunction among cancer survivors is high and the extent varies 
according to years of survival, disease site, age and sex of the patients. It should therefore be 
borne in mind that almost all oncology patients have sexual issues. There is need for 
improvement in the routine assessment of sexual functions among cancer survivors. To 
enhance this, training on basic assessment techniques including communication should be 
undergone by all those who partake in the care of cancer patients. There is also need for 
increased training in management of sexual issues and management techniques should be 
improved upon through further research for effectiveness. 
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